ArticleScientific reports2026
Harnessing Bacillus inaquosorum AGSP2 for enhancing ω-transaminase production through classical and AI-supported statistical design.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The synthesis of chiral amines is crucial since they are a key component in nearly 40% of top-selling drugs. ω-transaminases are promising biocatalysts for producing these chiral amines. This study reports the isolation of a wild-type Bacillus strain (Bacillus inaquosorum AGSP2) from a contaminated site at the Amlakhadi river, Gujarat, India. We optimized ω-transaminase production using both One Factor at a Time and Response Surface Methodology- Central Composite Design (RSM-CCD) techniques, with further model validation via an Artificial Intelligence (AI) tool, Support Vector Machine. The optimal medium, called Modified Luria-Bertani, contains fructose (12 g/L), NaCl (7.5 g/L), yeast extract (7.5 g/L), peptone (12 g/L), and α-methylbenzylamine (5 mM). Optimization increased ω-transaminase production 2.8 times, reaching an activity of 6121.88 ± 42 U/ml at 37 °C, pH 7, 120 rpm, with 2% (v/v) inoculum. The RSM-CCD model had R2 = 0.95, predicted R2 = 0.78, RMSE = 0.2327, while SVM achieved R2 = 0.99, predicted R2 = 0.96, RMSE = 0.1327. AGSP2 catalyzed the biotransformation of acetophenone with (S)-α-methylbenzylamine, resulting in a 53.32% conversion rate. These findings demonstrate the potential of combining statistical and AI tools to improve biocatalyst production and applications, presenting a sustainable approach for chiral amine synthesis and highlighting ω-transaminase's role in green biocatalysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.